Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer, namely, CNDO-201 or Trichuris suis ova (TSO) and CNDO-109. As of December 31, 2014, TSO, the microscopic eggs of the porcine whipworm, was in Phase II study stage for the treatment of immune-mediated diseases, such as Crohn’s disease (CD), ulcerative colitis (UC) or autism spectrum disorder (ASD). The Company’s CNDO-109 is a biologic that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells, and, as of December 31, 2014, was in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML). The Company’s subsidiary, Journey Medical Corporation (JMC), focuses on acquiring, developing, licensing and commercializing branded dermatology products.
